Net Loss per Share

3 Months Ended

Mar. 31, 2026

Earnings Per Share [Abstract]

Net Loss per Share

Net Loss per Share

The following table shows total outstanding potentially dilutive shares excluded from the computation of diluted loss per share as their effect would be anti-dilutive, as of March 31, 2026 and 2025:

	March 31,
	2026	2025
	(in thousands)
Options to purchase common stock	3,242	3,822
Performance-based awards and restricted stock units	7,949	9,974
Employee stock purchase plan	79	98
Contingent consideration	628	—
Total	11,898	13,894

As of March 31, 2026, the Company finalized a post-closing working capital adjustment related to the acquisition of Foresight Diagnostics. Certain escrowed shares that were returned to the Company in the second quarter of 2026 have been excluded from the calculation of basic and diluted earnings per share.